TECHNOLOGY
HEALER™ enables clinical development of Resolvin E1 therapeutics
Novel RvE1 Compound
Resolvins in their natural form as lipids are unstable, oily substances that are difficult to make into drugs.
Our HEALER™ chemistry platform (High Efficiency Amino Lipid Enabled Release) overcomes this fundamental obstacle by transforming resolvins including RvE1 into new molecules with vastly improved physical and chemical properties.
Our lead HEALER molecule is TP-317, a stable, highly water-soluble amino acid chelate salt of RvE1 that is protected by composition of matter patents across major markets.
Enables Clinical Development
For our clinical programs in IBD and cancer, we have developed TP-317 as an enteric-coated oral tablet that releases RvE1 in the upper intestine, facilitating its absorption into systemic circulation. Our technology also encompasses a novel synthetic route that supports production of TP-317 for clinical trials.
A Phase 1a study in healthy subjects with the novel TP-317 enteric-coated tablet showed a favorable safety and tolerability profile and proved effective in delivery of RvE1 to systemic circulation.